← Oncology Approval Tracker

FDA DECISION ·

Welireg

belzutifan · Merck

FDA approvalNew or expanded indicationPheochromocytoma and paraganglioma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults and children age 12 years or older with pheochromocytoma or paraganglioma that is locally advanced, unresectable, or metastatic.

LAMPGEN ANALYSIS

Why it matters

This label expansion introduced an oral HIF-2α inhibitor to a rare neuroendocrine tumor population.

What research teams should watch

Design referral from endocrinology and oncology and build anemia and oxygenation checks into visit schedules.

PRIMARY RECORDS

Sources